REGENXBIO INC. DL-,0001RR

REGENXBIO INC. DL-,0001

7.05EURD
+0.15+2.17%
At close at 10:26 GMT
EUR
No trades
See on Supercharts

RB0 fundamentals

Key facts

Market capitalization‪345.03 M‬EUR
Basic EPS (TTM)−4.52EUR
Founded2008
CEOCurran M. Simpson
About

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Ownership
‪‪49.55 M‬‬
Free Float shares
‪‪44.71 M‬‬ (90.24%)
Closely held shares
‪‪4.84 M‬‬ (9.76%)
Free Float shares
‪‪44.71 M‬‬ (90.24%)
Closely held shares
‪‪4.84 M‬‬ (9.76%)
Capital structure
Market cap
‪‪345.03 M‬‬
Debt
‪‪130.96 M‬‬
Cash & equivalents
‪‪229.44 M‬‬
Enterprise value
‪‪246.55 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪345.03 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
4.36x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
4.36x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪3.00‬
‪6.00‬
‪9.00‬
‪12.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−440%‬
‪−380%‬
‪−320%‬
‪−260%‬
‪−200%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−90.00 M‬‬
‪‪−60.00 M‬‬
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−75.00 M‬‬
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−75.00 M‬‬
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Gene Therapy
By country
Period: 2023
International
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪8.00 M‬‬
‪‪16.00 M‬‬
‪‪24.00 M‬‬
‪‪32.00 M‬‬
Actual
Estimate
Earnings
Next:Mar 4, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−1.40‬
‪−1.05‬
‪−0.70‬
‪−0.35‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

RB0 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
‪‪320.00 M‬‬
Assets
Liabilities